Satoko Kumada

Dr. Satoko Kumada


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MFMitsumasa Fukuda
Mitsumasa Fukuda
TMTakeshi Matsuo
Takeshi Matsuo
SFSo Fujimoto
So Fujimoto
HKHirofumi Kashii
Hirofumi Kashii
AHAi Hoshino
Ai Hoshino
SKSatoko Kumada
Satoko Kumada
Vagus nerve stimulation (VNS) is a palliative treatment for drug-resistant epilepsy (DRE) that has been in use for over two decades. VNS suppresses epileptic seizures, prevents emotional disorders, and improves cognitive function and sleep quality, a parallel effect associated with the control of epileptic seizures. The seizure suppression rate with VNS increases monthly to annually, and the incidence of side effects reduces over time. This method is effective in treating DRE in children as well as adults, such as epilepsy associated with tuberous sclerosis, Dravet syndrome, and Lennox–Gastaut syndrome. In children, it has been reported that seizures decreased by >70% approximately 8 years after initiating VNS, and the 50% responder rate was reported to be approximately 70%. VNS regulates stimulation and has multiple useful systems, including self-seizure suppression using magnets, additional stimulation using an automatic seizure detection system, different stimulation settings for day and night, and an automatic stimulation adjustment system that reduces hospital visits. VNS suppresses seizures and has beneficial behavioral effects in children with DRE. This review describes the VNS system, the mechanism of the therapeutic effect, the specific stimulation adjustment method, antiepileptic effects, and other clinical effects in patients with childhood DRE.

1 January 2021 in Epilepsy & Behavior Reports
Verified
Journal Article
Open access
AAAtsuko Arisaka
Atsuko Arisaka
MNMitsuko Nakashima
Mitsuko Nakashima
SKSatoko Kumada
Satoko Kumada
KIKenji Inoue
Kenji Inoue
HNHiroya Nishida
Hiroya Nishida
MFMitsumasa Fukuda
Mitsumasa Fukuda
• Epileptic-dyskinetic encephalopathies are rare epileptic disorders characterized by EOEE with involuntary movement. • The presence of involuntary movements in patients with EOEE caused by gene variants may be a key diagnostic symptom. • Genetic diagnosis is useful and may provide a reference for treatment selection.

1 March 2021 in Early Human Development
Verified
Journal Article
Closed access
AOAkihisa Okumura
Akihisa Okumura
YKYukihiro Kitai
Yukihiro Kitai
HAHiroshi Arai
Hiroshi Arai
MHMasahiro Hayakawa
Masahiro Hayakawa
YMYoshihiro Maruo
Yoshihiro Maruo
IMIchiro Morioka
Ichiro Morioka

22 January 2022 in Epilepsy & Behavior Reports
Verified
Journal Article
Open access
AMAko Matsuhashi
Ako Matsuhashi
TMTakeshi Matsuo
Takeshi Matsuo
SKSatoko Kumada
Satoko Kumada
• Coherence calculated from scalp EEG may be utilized to evaluate functional connectivity. • Functional connectivity decreased stepwise after anterior/posterior callosotomy. • Correlation was seen between functional connectivity and seizure frequency change. • Functional connectivity may reflect seizure outcome of callosotomy.

25 August 2019 in Neurology and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
YMYohane Miyata
Yohane Miyata
KHKohei Hamanaka
Kohei Hamanaka
SKSatoko Kumada
Satoko Kumada
SUShumpei Uchino
Shumpei Uchino
FYFusako Yokochi
Fusako Yokochi
NMNaomichi Matsumoto
Naomichi Matsumoto

23 July 2025 in Life
Verified
Journal Article
Open access
PDF file
YAYuichi Abe
Yuichi Abe
THToshimitsu Hamasaki
Toshimitsu Hamasaki
JNJun Natsume
Jun Natsume
YMYukiko Mogami
Yukiko Mogami
KMKei Murayama
Kei Murayama
AOAkira Ohtake
Akira Ohtake
An explorative study was conducted to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride combined with sodium ferrous citrate (SPP-004) in 10 pediatric patients with Leigh syndrome (LS) aged 3–24 months in 10 institutions between December 2014 and July 2019. The patients were randomized and allocated to the SPP-004 or placebo group for a 12-week double-blind period, followed by a 12-week open-label period with SPP-004 and then a long-term study of up to 180 weeks. The efficacy and safety were evaluated using the Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) and adverse events (AEs), respectively. No significant differences were found between groups in NPMDS scores, but prolonged SPP-004 treatment stabilized or improved scores. During the initial double-blind phase, the serum lactate levels increased in the placebo group but not in the SPP-004 group. Over the period of prolonged treatment with SPP-004, the average serum lactate level gradually decreased to a normal level. One patient died due to heart failure, presumably due to an underlying disease. Overall, 7 out of 10 patients received SPP-004 without developing severe AEs until the termination of the long-term study. Given the severe symptoms and poor prognosis of pediatric LS, NPMDS scores were indicative of stabilization in pediatric LS patients treated with SPP-004.